Various recombinant antigens designed by CTCVAC are analyzed by In-silico modeling and evaluated their antigenicity in the immune system.
Based on these results of the evaluation, we develop vaccine formulation.
Design of recombinant protein based on CTCVAC’s genetic DB for various infectious pathogen and protein production using expression
system are the core technology of CTCVAC R&D Center.

• Streptococcus suis Vaccine (ATOMSSUISpenta) - ATOMSSUISpenta is a multiple antigen fusion vaccine against S. suis based on five conserved
  antigens. It provides protection against different serotypes of S.suis.
• CTCVAC Verotox - CTCVAC conducts design & purification of the recombinant Stx2e, which is the major known agent that causes edema
  disease in pigs.